Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials, including clinical measurement, as well as project and data management services, such as reporting, administration, and support. The company serves clinicians for the diagnosis and management of human diseases; and pharmaceutical companies for their clinical trials. Resonance Health Limited has collaboration with Perth Radiological Clinic for the sharing of data and the training of neural networks to assess the viability of the development of various screening tools. The company is headquartered in Burswood, Australia.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 8 9286 5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.62 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Resonance Health (ASX:RHT) Frequently Asked Questions
What is Resonance Health's stock symbol?
Resonance Health trades on the ASX under the ticker symbol "RHT."
Has Resonance Health been receiving favorable news coverage?
Headlines about RHT stock have been trending positive on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Resonance Health earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Resonance Health.
Who are some of Resonance Health's key competitors?
Some companies that are related to Resonance Health include Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Advanced Oncotherapy (AVO), MRI Interventions (MRIC), Patient Home Monitoring (PTQ), REVA Medical (RVA), Kromek Group (KMK), Protech Home Medical (PHM), Oventus Medical (OVN), Helius Medical Technologies (HSM) and Impedimed (IPD).
What other stocks do shareholders of Resonance Health own?
Who are Resonance Health's key executives?
Resonance Health's management team includes the folowing people:
- Ms. Alison Laws, Chief Exec. Officer
- Mr. Agha Shahzad Pervez B.Sc., CFO & Company Sec.
- Dr. Timothy Guy St. Pierre, Chief Scientific Officer
- Ms. Celine Royet, Quality Assurance & Regulatory Affairs Mang.
- Dr. Jason Loveridge B.Sc, Ph.D., FRSM, Corp. Advisor
How big of a company is Resonance Health?
What is Resonance Health's official website?
How can I contact Resonance Health?
The company can be reached via phone at 61 8 9286 5300.
MarketBeat Community Rating for Resonance Health (ASX RHT)
MarketBeat's community ratings are surveys of what our community members think about Resonance Health and other stocks. Vote "Outperform" if you believe RHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RHT will underperform the S&P 500 over the long term. You may vote once every thirty days.
